Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Paul A. Heidenreich, Pamela B. Morris, Khurram Nasir, Erin D. Michos, Vera A. Bittner, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

56 Citations (Scopus)
Original languageEnglish
Pages (from-to)2572-2574
Number of pages3
Issue number25
Publication statusPublished - 20 Jun 2017
Externally publishedYes


  • cardiovascular disease
  • cholesterol
  • lipids

Cite this